Neurologic symptoms and signs observed in critical COVID-19 patients may be precursors of existing cerebrovascular disease

Yıl 2022, Cilt: 5 Sayı: 6, 1644 - 1649, 25.10.2022

Ayşe Yılmaz , Veysel Garani Soylu , Ufuk Demir , Öztürk Taşkın , Zahide Doğanay

https://doi.org/10.32322/jhsm.1180623

Öz

Introduction: Although COVID-19 disease often includes respiratory system findings, that affects the gastrointestinal system, circulatory system, coagulation system and neurological system. In this study, we identified the neurological signs and symptoms observed in critical COVID-19 patients.
Material and Method: This retrospective study reviewed 595 COVID-19 patients admitted to our intensive care unit (ICU) between January to June 2020. Patients with neurologic symptoms that were divided into two groups were diagnosed neurological disease (group ND) and non-neurological disease (group non-ND). Clinical signs and symptoms, radiological findings, demographic data (age, gender, presence of comorbidities), white blood cell (WBC), lymphocyte, platelet, lactic acid, glucose, and D-dimer levels, length of hospitalization, requirement of mechanical ventilation, and mortality were recorded for each patient.
Results: Neurologic symptoms were observed in 148 (24.8%) patients. Of these, 44 patients were diagnosed neurological disease and 104 patients were non- neurological disease. The prevalence of neurologic symptoms was significantly higher in group ND. The rate of acute ischemic cerebrovascular disease in 595 critical COVID-19 patients was 6.2%.
Conclusion: Presence of cerebrovascular diseases should be suspected in COVID-19patients with paresis, altered consciousness, numbness, taste/smell disorders, and plegia. The rate of ischemic cerebrovascular disease was approximately seven times higher than the rate of hemorrhagic cerebrovascular disease in critically COVID-19 patients.

Anahtar Kelimeler

Intensive care unit, neurology, COVID-19, acute ischemic stroke

Kaynakça

• Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: where are we now? Acta Trop 2021; 214: 105778.
• Akbarialiabad H, Taghrir MH, Abdollahi A, et al. Long COVID, a comprehensive systematic scoping review. Infection 2021; 49: 1163-86.
• Beghi E, Giussani G, Westenberg E, et al. Acute and postacute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. J Neurol 2022; 269: 2265-74.
• Wenting A, Gruters A, van Os Y, et al. COVID-19 neurological manifestations and underlying mechanisms: a scoping review. Front Psychiatry 2020; 11: 860.
• Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology 2020; 296: 0–20.
• Salahuddin H, Afreen E, Sheikh IS, et al. Neurological predictors of clinical outcomes in hospitalized patients with COVID-19. Front Neurol 2020; 11: 585944.
• Republic of Turkey Ministry of Health; Https://COVID19.Saglik.gov.tr/Eklenti/40719/0/COVID-19rehberieriskinhastayonetimivetedavipdf.pdf Access Date: 07 May 2021.
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-Cov-2 admitted to icus of the Lombardy region, Italy. JAMA 2020; 32: 1574-81.
• Kokoszka-Bargieł I, Cyprys P, Rutkowska K, et al. Intensive care unit admissions during the first 3 months of the COVID-19 pandemic in Poland: a single-center, cross-sectional study. Med Sci Monit 2020; 26: E926974.
• Xudong X, Junzhu C, Xingxiang W, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci 2006; 78: 2166–71.
• Mahat RK, Panda S, Rathore V, et al. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Epidemiol Glob Health 2021; 11: 100727.
• Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol 2020; 5: 279-84.
• Desforges M, Le Coupanec A, Dubeau P, et al. Coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?. Viruses 2019; 12: 14.
• Fodoulian L, Tuberosa J, Rossier D, et al. SARS-Cov-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium and brain. iScience 2020; 18: 101839.
• Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Strok Res 2020; 11: 322–5.
• Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683-90.
• Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-Cov-2 infection. N Engl J Med 2020; 382: 2268-70.
• Li Y, Wang M, Zhou Y. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol 2020; 5: 279-84.
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–13.
• Amanat M, Rezaei N, Roozbeh M, et al. Neurologic manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurol 2021; 21: 116.
• Chang CC, Yang MH, Chang SM, et al. Clinical significance of olfactory dysfunction in patients of COVID-19. J Chin Med Assoc 2021; 84: 682-9.
• Whittaker A, Anson M, Harky A. Neurologic manifestations Of COVID-19: a systematic review and current update. Acta Neurol Scand 2020; 142: 14–22.
• Yaghi S, Ishida K, Torres J, et al. SARS-Cov-2 and stroke in a New York Healthcare System. Stroke 2020; 51: 2002–11.
• Toscano G, Palmerini F, Ravaglia S Guillain-Barré syndrome associated with SARS-Cov-2. N Engl J Med 2020; 382: 2574-6.
• Li YC, Zhang Y, Tan BH. What can cerebrospinal fluid testing and brain autopsies tell us about viral neuroinvasion of SARS-Cov-2. Med Virol 2021; 9: 4247-57.
• Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475-82.
• Hernández-Fernández F, Valencia HS, Barbella-Aponte R. A cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020; 143: 3089–103
• Meppiel E, Peiffer-Smadja N, Maury A. Neurologic manifestations associated with COVID-19: a multicentre registry. Clin Microbiol Infect 2021; 27: 458-66.
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–7.
• Eray U, Ayrıbaş B, Çağlar ÖF, Hacıoğlu T, Alibeyoğlu F. Post-COVID syndrome? COVID-19survivors suffer from cognitive difficulties, somatic complaints and anxiety. J Health Sci Med 2022; 5: 1328-33.